PTGX logo

PTGX Protagonist Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$123.81
-1.01 (-0.81%)

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for …

Market Cap: $8.08Bwww.protagonist-inc.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
54
4 mentions
—
60d
58
5 mentions
—
90d
45
15 mentions
—
news: 9 · rss: 6

Analyst Ratings

26 analysts
Buyconsensus
Strong Buy 0Buy 26Hold 0Sell 0Strong Sell 0
Avg price target$175.33+41.6%
Low $160Median $173High $190
Current Consensus

Revenue

$274.41M
$-8.19M$86.01M$180.21M$274.41M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.96
$-2.22–$-1.39
7 analysts
FY2026
$5.14
$4.29–$6.80
8 analysts
FY2027
$-0.04-101% YoY
$-0.23–$0.03
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Dinesh V. Patel
Sector
Healthcare
Industry
Biotechnology
Employees
141
Beta
1.79
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
81.79
www.protagonist-inc.com